Who is sponsoring NCT03351842?

NCT03351842 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT03351842?

Interventions in NCT03351842: cis Platinum/Carboplatin, Pemetrexed Disodium, Undergo surgery.

What condition does NCT03351842 study?

NCT03351842 studies Chemotherapy, Adjuvant, Lung Adenocarcinoma, Stage I, Treatment, Histological Type of Neoplasm.

Is NCT03351842 still recruiting?

NCT03351842 is currently recruiting now. Last updated 19 December 2017.

Last reviewed 2017-12-19 · How we verify

NCT03351842

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%

Recruiting now Phase 2 Last updated 19 December 2017

What this trial tests

Phase 2 trial testing cis Platinum/Carboplatin, Pemetrexed Disodium in Chemotherapy, Adjuvant in 460 participants. Currently enrolling.

Timeline

1 September 2017

Primary endpoint
1 September 2019

1 September 2024

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	460
Start date	1 September 2017
Primary completion	1 September 2019
Estimated completion	1 September 2024
Sites	1 location across China

Drugs / interventions tested

cis Platinum/Carboplatin, Pemetrexed Disodium — full drug profile →
Undergo surgery

Conditions studied

Chemotherapy, Adjuvant — all drugs for Chemotherapy, Adjuvant →
Lung Adenocarcinoma, Stage I — all drugs for Lung Adenocarcinoma, Stage I →
Treatment — all drugs for Treatment →
Histological Type of Neoplasm — all drugs for Histological Type of Neoplasm →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

Adults 19 to 70, any sex, with Chemotherapy, Adjuvant or Lung Adenocarcinoma, Stage I. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer.
Yu X, Dong Z, Wang W, Mao S, et al · · 2021 · cited 6× · PMID 34040439 · DOI 10.2147/cmar.s302545
Randomized controlled trials in lung cancer surgery: How are we doing?
Wong LY, Li Y, Elliott IA, Backhus LM, et al · · 2024 · cited 1× · PMID 38690441 · DOI 10.1016/j.xjon.2024.01.008

Verify or expand the search:

Other recruiting trials for Chemotherapy, Adjuvant

Currently open trials in the same condition.

NCT06790238 — POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + · active not recruiting
NCT06369194 — POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol · active not recruiting

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03351842 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 19 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03351842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing